WO1991019743A3 - Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals - Google Patents

Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals Download PDF

Info

Publication number
WO1991019743A3
WO1991019743A3 PCT/US1991/004181 US9104181W WO9119743A3 WO 1991019743 A3 WO1991019743 A3 WO 1991019743A3 US 9104181 W US9104181 W US 9104181W WO 9119743 A3 WO9119743 A3 WO 9119743A3
Authority
WO
WIPO (PCT)
Prior art keywords
gnrh
mammals
gonadotropin
levels
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/004181
Other languages
French (fr)
Other versions
WO1991019743A2 (en
Inventor
Gary D Hodgen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Priority to AU80616/91A priority Critical patent/AU660617B2/en
Priority to JP91511508A priority patent/JPH05507493A/en
Priority to DE69107306T priority patent/DE69107306T2/en
Priority to CA002084060A priority patent/CA2084060C/en
Priority to EP91911617A priority patent/EP0536203B1/en
Publication of WO1991019743A2 publication Critical patent/WO1991019743A2/en
Publication of WO1991019743A3 publication Critical patent/WO1991019743A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a method of controlling gonadotropin levels in mammals which comprises administering a gonadotropin releasing hormone (GnRH) antagonist in an amount and frequency effective to substantially suppress endogenous gonadotropin levels in said mammal and administering gonadotropin releasing hormone (GnRH) in an amount and frequency effective to induce secretion of gonadotropins to maintain a desired level in said mammal. This method is especially useful for treating mammals, particularly women, who suffer from polycystic ovarian disease or hyperandrogenism, or who otherwise have abnormally high levels of luteinizing hormone which it is desired to reduce to approximately normal levels. The method of this invention is particularly advantageous for inducing ovulation in mammals, particularly women, that have the above-mentioned problems. The preferred GnRH antagonists for use in the present invention include Antide and its analogs, which exhibit long term gonadotropin suppression.
PCT/US1991/004181 1990-06-14 1991-06-12 COMBINED TREATMENT WITH GnRH ANTAGONIST AND GnRH TO CONTROL GONADOTROPIN LEVELS IN MAMMALS Ceased WO1991019743A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU80616/91A AU660617B2 (en) 1990-06-14 1991-06-12 Combined treatment with GnRH antagonist and GnRH to control gonadotropin levels in mammals
JP91511508A JPH05507493A (en) 1990-06-14 1991-06-12 Combination therapy with GnRH antagonists and GnRH to modulate gonadotropin levels in mammals
DE69107306T DE69107306T2 (en) 1990-06-14 1991-06-12 COMBINED TREATMENT WITH A GNR ANTAGONIST AND GNR FOR REGULATING GONADOTROPINE LEVELS IN MAMMALS.
CA002084060A CA2084060C (en) 1990-06-14 1991-06-12 Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals
EP91911617A EP0536203B1 (en) 1990-06-14 1991-06-12 COMBINED TREATMENT WITH GnRH ANTAGONIST AND GnRH TO CONTROL GONADOTROPIN LEVELS IN MAMMALS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US538,375 1983-10-03
US07/538,375 US5180711A (en) 1990-06-14 1990-06-14 Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals

Publications (2)

Publication Number Publication Date
WO1991019743A2 WO1991019743A2 (en) 1991-12-26
WO1991019743A3 true WO1991019743A3 (en) 1992-02-20

Family

ID=24146670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004181 Ceased WO1991019743A2 (en) 1990-06-14 1991-06-12 COMBINED TREATMENT WITH GnRH ANTAGONIST AND GnRH TO CONTROL GONADOTROPIN LEVELS IN MAMMALS

Country Status (10)

Country Link
US (1) US5180711A (en)
EP (1) EP0536203B1 (en)
JP (1) JPH05507493A (en)
AT (1) ATE118171T1 (en)
AU (1) AU660617B2 (en)
CA (1) CA2084060C (en)
DE (1) DE69107306T2 (en)
DK (1) DK0536203T3 (en)
ES (1) ES2067940T3 (en)
WO (1) WO1991019743A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
DE4305225A1 (en) * 1993-02-19 1994-08-25 Asta Medica Ag New manufacturing process for Cetrorelix lyophilisate
US5824286A (en) * 1994-04-26 1998-10-20 The Medical College Of Hampton Roads Mammography method
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5589457A (en) * 1995-07-03 1996-12-31 Ausa International, Inc. Process for the synchronization of ovulation
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US6455499B1 (en) 1999-02-23 2002-09-24 Indiana University Foundation Methods for treating disorders associated with LHRH activity
US6703367B1 (en) 1999-04-27 2004-03-09 Praecis Pharmaceuticals Inc. Methods for treating hot flashes and gynaecomastia
US6598784B2 (en) * 2000-12-20 2003-07-29 Meadwestvaco Packaging Syatens, Llc Beverage carton with strap type carrying handle
PT1684782E (en) 2003-10-03 2015-12-21 Thorn Bioscience Llc Process for the synchronization of ovulation for timed breeding without heat detection
US20070197435A1 (en) * 2006-02-17 2007-08-23 Webel Stephen K Process for the synchronization of ovulation for timed breeding without heat detection
RU2568839C2 (en) 2009-04-23 2015-11-20 ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК Method and composition for synchronising insemination time
DK2925339T3 (en) 2012-11-28 2020-07-20 United Ah Ii Llc Method for synchronizing insemination time in gilts
CN107441587A (en) * 2016-05-31 2017-12-08 上海微创生命科技有限公司 Infusion pump

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0161063A1 (en) * 1984-04-03 1985-11-13 Serono Laboratories, Inc. Method of inducing ovulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845077A (en) * 1984-04-03 1989-07-04 Serono Laboratories, Inc. Method of inducing ovulation
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0161063A1 (en) * 1984-04-03 1985-11-13 Serono Laboratories, Inc. Method of inducing ovulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FERTILIY AND STERILITY vol. 54, no. 6, December 1990, pages 1140 - 1145; KEITH GORDON ET AL.: 'A novel regimen of gonadotropin-releasing hormone antagonist plus pulsatile GnRh. controlled restoration of gonadotropin secretion and ovulation induction' *

Also Published As

Publication number Publication date
ATE118171T1 (en) 1995-02-15
ES2067940T3 (en) 1995-04-01
DE69107306D1 (en) 1995-03-23
EP0536203B1 (en) 1995-02-08
DK0536203T3 (en) 1995-04-10
AU8061691A (en) 1992-01-07
EP0536203A1 (en) 1993-04-14
US5180711A (en) 1993-01-19
WO1991019743A2 (en) 1991-12-26
CA2084060A1 (en) 1991-12-15
DE69107306T2 (en) 1995-06-08
JPH05507493A (en) 1993-10-28
CA2084060C (en) 2000-05-16
AU660617B2 (en) 1995-07-06

Similar Documents

Publication Publication Date Title
WO1991019743A3 (en) Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals
Darendeliler et al. Growth hormone increases rate of pubertal maturation
DE69724682T2 (en) Use of gonadotropin releasing hormone analogues or similar compounds for the production of pharmaceutical preparations as an additive for invasive treatment of carcinomas
Feldberg et al. Ovarian cyst formation: a complication of gonadotropin-releasing hormone agonist therapy
RIVIER et al. Chronic effects of [D-Trp6-Pro9-NEt] luteinizing hormone-releasing factor on reproductive processes in the female rat
DE69912422T2 (en) METHOD FOR TREATING FERTILITY DISORDERS
RU2000129658A (en) METHOD FOR THERAPEUTIC INFERTILITY TREATMENT
HEBER et al. GONADOTROPIN-RELEASING HORMONE ANALOG AND TESTOSTERONE SYNERG1STICALLY INHIBIT SPERMATOGENESIS
Rivier et al. Effects of gonadotropin releasing hormone agonists and antagonists on reproductive functions
Gay The hypothalamus: physiology and clinical use of releasing factors
Bartke Differential requirement for prolactin during pregnancy in the mouse
Spies et al. Pituitary and uterine factors controlling regression of corpora lutea in intact and hypophysectomized rabbits
Zanisi et al. Interaction of oestrogen and of physiological progesterone metabolites in the control of gonadotropin secretion
EP0788799A2 (en) LHRH-Antagonists in the treatment of fertility disorders
Celotti et al. Effect of prolactin on LH release in male rats
Cassidenti et al. Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: a preliminary report
Imai et al. Is extrapituitary action of gonadotrophin-releasing hormone biologically significant?
Vacher Gn-RH agonists in the treatment of prostatic carcinoma
Akagbosu The use of GnRH agonists and antagonists in infertility
Rajfer et al. Effects of Chronic D-Leu6, des-GIy10-Gonadotropin Releasing Hormone Ethylamide on Male Sex Tissues
Brauner et al. Should All Girls with Central Precocious Puberty be Treated by LHRH Analogue?
Kozlowska et al. Localization of substance P, calcitonin gene related peptide and galanin in the nerve fibers of porcine cystic ovaries
Felberbaum et al. Entwicklung und Anwendung der GnRH-Analoga in der Sterilitätstherapie
Crowder Regulation of the secretion of luteinizing hormone and follicle-stimulating hormone in the ewe.
Tanaka et al. Bone maturation during human growth hormone (GH)-treated GH deficient boys with and without gonadal suppression treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2084060

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991911617

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991911617

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991911617

Country of ref document: EP